Franç Is Lemonnier

Title: Franç Is Lemonnier: Innovator in Immunogenic Peptides

Introduction

Franç Is Lemonnier is a notable inventor based in Bourg la Reine, France. He has made significant contributions to the field of immunology, particularly in the development of therapeutic vaccines. His work focuses on optimizing immunogenic peptides for the treatment and prevention of leukemia in humans.

Latest Patents

Lemonnier holds a patent for "Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof." This invention involves the optimization of the wild R9M peptide, which is crucial for therapeutic and preventive vaccination against leukemia. The patent details the creation of mutated immunogenic peptides derived from the human TEL/AML1 fusion protein, specifically the wild R9M peptide sequence Arg-Ile-Ala-Glu-Cys-Ile-Leu-Gly-Met. It also encompasses polynucleotides coding for these peptides, cellular expression vectors, and antibodies that can bind to the peptides or polynucleotides. The invention aims to prepare vaccines and anti-tumoral medicines, enhancing the immune response in humans.

Career Highlights

Throughout his career, Franç Is Lemonnier has worked with prestigious institutions such as the National Institute of Health and Medical Research and Institut Pasteur. His research has significantly advanced the understanding of immunogenic peptides and their applications in cancer treatment.

Collaborations

Lemonnier has collaborated with esteemed colleagues, including Pierre Rohrlich and Patricia Yotnda. These partnerships have contributed to the success of his research and the development of innovative therapeutic solutions.

Conclusion

Franç Is Lemonnier's work in the field of immunogenic peptides represents a significant advancement in therapeutic vaccination against leukemia. His innovative approach and dedication to research continue to impact the medical community positively.